Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Ovarian cancer Clinical Trials

Protocol Number Title
2006LS032
MT2005-21 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
2006NT001
WCC 60 Biomarker with Biological Function in Ovarian Carcinoma/Diagnostic Markers for Ovarian Cancer: Detection of Novel Cell Adhesion Proteins in Patients' Specimens
2011NTLS041
Molecular Epidemiology of Pediatric Germ Cell Tumors
2011NTLS157
Use of Pap test samples to study human diseases
2014IS121
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer
2014NTLS003
Identification of Changes in Gene Expression of Epithelial Ovarian Cancer Tumors after Neoadjuvant Chemotherapy: Application of RNA-Seq Transcriptome Analysis, a Pilot Study
2014NTLS004
Mobile Phone Technology to Increase Genetic Counseling for Women with Ovarian Cancer and Their Families
2014NTLS069
Personalized mouse models of chemotherapy resistance in ovarian cancer
2015CG094
Molecular Analysis for Therapy Choice (MATCH)
2015IS019
A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
2016CG020
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
2016IS013
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

12 trials displayed